Supporting Patients Suffering With IBS

The probiotic blend i3.1 is specifically formulated to help manage symptoms of Irritable Bowel Syndrome (IBS).

  • 3 billion clinically researched bacteria

  • 3 live strains - Pediococcus acidilactici CECT 7483, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485

Multiple mechanisms of action:

  1. Reduction of intestinal permeability​ – decreasing both diarrhoea and visceral sensitivity 

  2. Dysbiosis correction, helps reduce opportunistic bacteria – for a more balanced microbiota, contributing to normalizing bowel transit and visceral sensitivity 

  3. Reduction of inflammation and hypersensitivity – helps with the visceral sensitivity associated with IBS​

Efficacious after 3 weeks

No adverse effects and well-tolerated

Recommended by the World Gastrology Organisation

What is i3.1?

i3.1 is a collection of 3 bacterial strains, Pediococcus acidilactici CECT 7483, Lactobacillus plantarum CECT 7484 and Lactobacillus plantarum CECT 7485.


The probiotic formula has an innovative mechanism of action with a triple effect on elements of IBS pathophysiology (Lorenzo-Zúñiga, 2014) –

  1. Reduction of intestinal permeability; decrease both diarrhoea and visceral sensitivity

  2. Dysbiosis correction; for a more balance microbiota, contributing to normalising bowel transit and visceral sensitive

  3. Reduction of inflammation and hypersensitivity; helps reduce the visceral sensitivity associated with IBS


Image 1. Mechanisms of action of i3.1

i3.1 Research

Irritable Bowel Syndrome (IBS) is defined as recurrent abdominal pain associated with defecation or a change in bowel habits, often accompanied by symptoms of abdominal bloating (Lacy & Patel, 2017). Functional gastrointestinal disorders such as IBS are considered disorders of the gut-brain axis by the latest consensus guidelines (Rome-IV criteria) (Drossman, 2016). Therefore, the impact of IBS on peoples lives goes beyond specific gastrointestinal symptoms.


IBS patients suffer from increased visceral sensitivity, an alteration in pain signalling pathways. Visceral hypersensitivity produces an abnormal perception of pain caused by a stimulus that does not normally elicit pain (hyperalgesia), increased perception of intestinal gas beyond objective distention (subjective bloating) and increased worry about pain (gut-specific anxiety) (Chey et al., 2015). Visceral hypersensitivity is now recognized as a hallmark of functional bowel disorders by Rome-IV criteria (Lacy & Patel, 2017). The cause of visceral hypersensitivity is multifactorial, it is related to underlying changes in the microbiota, altered calcium channel expression, increased permeability and mast cell activation, as well as altered response of the central nervous system to stimuli from the gut (Crouzet et al., 2013; Fuentes & Christianson, 2016; González-Castro et al., 2017; Piche et al., 2008).


Due to the abnormal visceral sensitivity, symptomatology and related anxiety, the health-related quality of life of IBS patients is severely compromised. Quality of life of IBS subjects has been shown to be even more related to extraintestinal symptoms (headache, sleep disturbances, post-traumatic stress disorder, temporomandibular joint disorder, sicca syndrome, back/pelvic pain, myalgias, back pain, and chronic pelvic pain) than gastrointestinal symptoms (Rey et al., 2008; Spiegel et al., 2004) and can have a significant economic cost (Agarwal & Spiegel, 2011).


Therefore, successful treatment for IBS should be targeting both the gastrointestinal symptoms as well as extraintestinal symptoms to target the condition as a whole.